HOME >> BIOLOGY >> NEWS
Compound inhibits one critical pathway in breast cancer growth

COLUMBUS, Ohio A compound that suppresses the growth of cancer cells and is relatively non-toxic to normal cells may one day be useful for treating several types of cancer, researchers report in this week's Proceedings of the National Academy of Sciences.

Laboratory experiments in human breast cancer cells suggest that the compound inhibits the constant activation of a protein called Stat3 that is found in several different types of cancer, including cancer of the breast, lung, prostate, head and neck, skin, pancreas and ovaries as well as lymphoma and certain kinds of leukemia.

Stat3 is constantly activated in about 60 percent of breast tumors, said Jiayuh Lin, the study's lead author and an associate professor of pediatrics at Ohio State University.

All cells contain Stat3 protein, but in normal cells, Stat3 activities are only turned on temporarily. Researchers do know, however, that Stat3 is constantly turned on in certain tumor cells.

"The cancer cells we studied seem to depend on Stat3 for survival," said Lin. "When we blocked the chain of events that activate Stat3, the cancer cells died."

Lin is also a member of Ohio State's Comprehensive Cancer Center and an investigator in the Center for Childhood Cancer at Columbus Children's Research Institute. He co-authored the study with Shaomeng Wang, Hui Song and Renxiao Wang, all with the University of Michigan Comprehensive Cancer Center.

The researchers named the compound STA-21. They tested STA-21 after using a computer program to narrow down a list of potential compounds to a manageable number that they could physically test in the lab.

When the computer screening process ended, the researchers tested the 100 top compounds. They tested these compounds on human breast cancer cells in order to find which one best stopped the constant Stat3 activation. STA-21 appeared to be the best inhibitor of Stat3 activity.

"This compound showed a remarkab
'"/>

Contact: Jiayuh Lin
linj@ccri.net
614-355-2652
Ohio State University
7-Mar-2005


Page: 1 2

Related biology news :

1. Scripps research scientists: Compounds show significant promise against potential bioweapon toxins
2. Compound eyes, evolutionary ties
3. Compounds in cranberry juice show promise as alternatives to antibiotics
4. Compound in wine reduces levels of Alzheimers disease-causing peptides
5. Compound reveals new link between signaling protein and cell migration
6. Compound from Chinese medicine shows promise in head and neck cancer
7. Animal study: Compounds in cranberries may have heart-healthy effects
8. Compound from Chinese medicine shows promise in head and neck cancer, U-M study finds
9. Compounds in plastic packaging act as environmental estrogens altering breast genes
10. Compound from rare plant shows promise in treating breast cancer
11. AVN944 inhibits IMPDH and induces apoptosis-related biomarkers in patients with hematologic cancers

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/4/2017)... Jan. 4, 2017  CES 2017 – Valencell ... technology, today announced the launch of two new ... the highly-accurate biometric sensor modules that incorporate the ... experience and expertise. The two new designs include ... for hearables, and Benchmark BW2.0, a 2-LED version ...
(Date:12/20/2016)... RALEIGH, N.C. and GENEVA, Dec, 20, 2016 ... performance biometric data sensor technology, and STMicroelectronics ... across the spectrum of electronics applications, announced today ... scalable development kit for biometric wearables that includes ... integrated with Valencell,s Benchmark™ biometric sensor ...
(Date:12/15/2016)... , December 15, 2016 Arvato ... an agreement with NuData Security, an award-winning international ... will enable clients to focus on good customer experience, balancing ... regulation. ... In order to provide a one-stop fraud prevention suite, Arvato ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... Linda, Ca (PRWEB) , ... January 18, 2017 ... ... virtual events for tech innovators, engineers, and scientists from around the world, was ... American News. The awards program is based entirely on merit and decided upon ...
(Date:1/19/2017)... , Jan. 18, 2017  Northwest Biotherapeutics, Inc. ... DCVax® personalized immune therapies for operable and inoperable solid ... , Chief Technical Officer of NW Bio, will present ... 19, 2017, at the Hyatt Regency Hotel in ... will chair the session entitled "New Therapeutic Approaches – ...
(Date:1/18/2017)... , January 18, 2017 According to a new ... Diagnosis, Neuroscience, Cytology, Infectious Disease), & End User (Molecular Diagnostic Laboratories, Academic and ... expected to reach USD 739.9 Million by 2021 from USD 557.1 Million in ... Reading ... MarketsandMarkets Logo ...
(Date:1/18/2017)... ... , ... Executive search firm Slone Partners proudly supports the ... advancement of the clinical trials segment. Hosted in Miami, this conference brings together ... management. , As executive talent specialists in the industries central to clinical ...
Breaking Biology Technology:
Cached News: